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Alterations of monocyte NF-κB p65/RelA
signaling in a cohort of older medical
patients, age-matched controls, and
healthy young adults
Juliette Tavenier1*, Line Jee Hartmann Rasmussen1,2, Morten Baltzer Houlind1,3,4, Aino Leegaard Andersen1,
Inge Panum5, Ove Andersen1,6,7*, Janne Petersen1,8,9, Anne Langkilde1 and Jan O. Nehlin1
Abstract
Background: Altered monocyte NF-κB signaling is a possible cause of inflammaging and driver of aging, however,
evidence from human aging studies is sparse. We assessed monocyte NF-κB signaling across different aging
trajectories by comparing healthy older adults to older adults with a recent emergency department (ED) admission
and to young adults.
Methods: We used data from: 52 older (≥65 years) Patients collected upon ED admission and at follow-up 30-days
after discharge; 52 age- and sex-matched Older Controls without recent hospitalization; and 60 healthy Young
Controls (20–35 years). Using flow cytometry, we assessed basal NF-κB phosphorylation (pNF-κB p65/RelA; Ser529)
and induction of pNF-κB following stimulation with LPS or TNF-α in monocytes. We assessed frailty (FI-OutRef),
physical and cognitive function, and plasma levels of IL-6, IL-18, TNF-α, and soluble urokinase plasminogen activator
receptor.
Results: Patients at follow-up were frailer, had higher levels of inflammatory markers and decreased physical and
cognitive function than Older Controls. Patients at follow-up had higher basal pNF-κB levels than Older Controls
(median fluorescence intensity (MFI): 125, IQR: 105–153 vs. MFI: 80, IQR: 71–90, p < 0.0001), and reduced pNF-κB
induction in response to LPS (mean pNF-κB MFI fold change calculated as the log10 ratio of LPS-stimulation to the
PBS-control: 0.10, 95% CI: 0.08 to 0.12 vs. 0.13, 95% CI: 0.10 to 0.15, p = 0.05) and TNF-α stimulation (0.02, 95% CI: −
0.00 to 0.05 vs. 0.10, 95% CI: 0.08 to 0.12, p < 0.0001). Older Controls had higher levels of inflammatory markers than
Young Controls, but basal pNF-κB MFI did not differ between Older and Young Controls (MFI: 81, IQR: 70–86; p = 0.72).
Older Controls had reduced pNF-κB induction in response to LPS and TNF-α compared to Young Controls (LPS: 0.40,
95% CI: 0.35 to 0.44, p < 0.0001; and TNF-α: 0.33, 95% CI: 0.27 to 0.40, p < 0.0001). In Older Controls, basal pNF-κB MFI
was associated with FI-OutRef (p = 0.02).
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Conclusions: Increased basal pNF-κB activity in monocytes could be involved in the processes of frailty and
accelerated aging. Furthermore, we show that monocyte NF-κB activation upon stimulation was impaired in frail older
adults, which could result in reduced immune responses and vaccine effectiveness.
Keywords: Aging, Monocyte, NF-κB, Immunosenescence, Chronic inflammation, Inflammaging
Background
Twenty years ago, Franceschi et al. coined the term
inflammaging in reference to the systemic, low-level in-
crease in levels of inflammatory markers with age [1].
Since then, many studies have shown associations be-
tween this state of chronic inflammation and the devel-
opment of frailty and most age-related chronic diseases
including cancer, diabetes, cardiovascular and neurode-
generative disease [2–5]. Chronic inflammation has also
emerged as a prognostic marker for mortality [6, 7].
However, the causes and effects of inflammaging are still
a matter of debate and intense research [5]. In parallel
with chronic inflammation, aging is associated with
immunosenescence, i.e. the age-related decline in im-
mune function [8]. Impaired innate immunity and
monocyte function has been implicated in the reduced
ability to fight viral and bacterial infections [9, 10] and
could also have consequences for responses to vaccin-
ation in older adults [11]. Immunosenescence is thought
to result in increased susceptibility to infections, a com-
mon cause of acute hospitalization and mortality in
older adults [12–14].
The transcription factor nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) is a master
regulator of inflammatory responses in innate immune
cells [15, 16]. Upon activation, NF-κB induces transcrip-
tion of pro-inflammatory genes and activates inflamma-
somes such as NOD-, LRR- and pyrin domain-
containing protein 3 (NLRP3). NF-κB (p65/RelA) also
acts as a master regulator of the senescence-associated
secretory phenotype (SASP) controlling both cell-
autonomous and non-cell-autonomous aspects of the
senescence program [17]. In inflammaging, the elevated
circulating levels of interleukin (IL)-6, IL-8, and tumor
necrosis factor-α (TNF-α) have been attributed to in-
creased NF-κB activity in innate immune cells such as
monocytes [18]. Much of this evidence is based studies
from animal models, and there is little direct evidence of
a link between monocyte NF-κB signaling and chronic
inflammation in human aging studies. Furthermore, due
to its central role in the regulation of immune responses,
altered NF-κB signaling could also be involved in the re-
duced monocyte responsiveness observed with age.
Much of the work examining changes to monocyte
function and signaling in aging has compared healthy
older adults with healthy younger adults [19–23]. How-
ever, aging is a highly heterogeneous process and there is a
considerable variability in the rate of aging across older
adults [24]. Studying older individuals on different trajec-
tories of aging could be beneficial to gain a better under-
standing of dysregulation of inflammatory and immune
responses in older adults and their potential role in the
aging process. This knowledge could also lead to the devel-
opment of improved anti-viral and anti-bacterial treatments
and to generating lifesaving vaccines that are also effective
in older populations. It has been suggested that age-related
chronic diseases and geriatric syndromes such as frailty
could be considered expressions of accelerated aging [25].
Frailty is characterized by the loss of physiological reserve
capacity as well as an increased vulnerability to stressors,
and is therefore highly prevalent among acutely hospitalized
older adults [26]. Thus, we hypothesized that older adults
requiring an Emergency Department visit could represent a
frailer population on a trajectory of accelerated aging com-
pared to an age-matched population without recent
hospitalization (Fig. 1).
Here, we aimed to evaluate the effects of chronological
age on monocyte NF-κB signaling (both basal levels and
activation upon stimulation with LPS or TNF-α) by
comparing healthy older adults to healthy young adults.
Furthermore, we aimed to investigate whether dysregu-
lated NF-κB signaling in monocytes is involved in the
aging process by comparing two groups of older adults
with different aging trajectories. Thus, we designed this
study to include three groups: one group of healthy
young adults and two groups of older adults. The two
groups of older adults consisted of (i) patients with a re-
cent unplanned Emergency Department (ED) visit, and
(ii) age- and sex-matched older adults without any re-
cent hospitalization (Fig. 1). We contemplated that, once
they have recovered from the acute illness, it would be-
come apparent that the older patients exhibited evident
signs of accelerated aging such as frailty, chronic inflam-
mation, decreased physical and cognitive function com-
pared to age- and sex-matched older adults without
recent hospitalization. Finally, we aimed to explore how
dysregulated monocyte NF-κB signaling contributes to
accelerated aging by investigating its associations with
inflammation, frailty, and physical and cognitive decline
in older adults.
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Methods
Study description
This study uses data collected as part of FAM-CPH, an
observational cohort study aiming to investigate mecha-
nisms of biological aging and chronic inflammation, as
well as malnutrition, and medication in acutely ill and
healthy older adults as well as healthy young adults. Pre-
vious results from FAM-CPH regarding drug prescrip-
tion have been published elsewhere [27]. FAM-CPH was
approved by the Health Research Ethics Committee for
the Capital Region of Denmark (H-16038786), the Da-
nish Data Protection Agency (AHH-2016-067) and was
registered at Clinicaltrials.gov (NCT03052192). The
study was conducted in accordance with the Declaration
of Helsinki, and all participants gave written informed
consent.
Study participants
Three groups of participants were recruited between
November 2016 and September 2019: (i) Patient
Group: older adults admitted to the ED due to acute
illness; (ii) Older Controls: older adults matched on
age and sex with participants from the Patient Group,
but with no hospital admissions in the 2 years preced-
ing inclusion; (iii) Young Controls: healthy adults
aged 20–35 years.
Patient group Inclusion criteria were: ≥65 years of age,
acutely admitted to the ED, able to speak and under-
stand Danish, caucasian. Exclusion criteria were: inability
to cooperate cognitively, terminal illness or illness
requiring isolation. For this FAM-CPH substudy, we
further excluded patients with autoimmune disease or
current cancer diagnosis, or patients who were
prescribed systemic immunosuppressive or anti-
inflammatory medication. Patients were included during
their admission to the ED at Copenhagen University
Hospital Hvidovre, Denmark. Blood samples and data
were collected upon hospital admission, as well as in the
patient’s home 30 days after discharge and 1 year after
the first follow-up visit.
Fig. 1 Study design and hypothesis. We evaluated the effect of chronological age on monocyte NF-κB signaling (p65/RelA S529 basal
phosphorylation levels and induction of phosphorylation upon TLR4 and TNF-R stimulation) by comparing Young to Older Controls. We
evaluated the role of monocyte NF-κB dysregulation in the aging process by comparison of two populations of older individuals with different
aging trajectories: recently hospitalized Patients (hypothesized to exhibit signs of accelerated aging) and age-matched Older Controls.
Furthermore, we explored whether the possible role of altered monocyte NF-κB signaling in aging was mediated by chronic inflammation, frailty,
physical and cognitive decline. We also tested whether CMV-infection was a confounder for the association of monocyte NF-κB signaling with
aging. Abbreviations: CMV: cytomegalovirus; TLR: Toll-like receptor; TNF-R: tumor necrosis factor receptor.
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Older controls Participants in the Older Control group
were included based on 1:1 matching on age and sex
with participants form the Patient Group at the 30-day
follow-up. We initially aimed to match Older Controls
and Patients by municipality of residence. Due to a lower
than expected response rate of Older Controls, this
could not be achieved. However, all Patients and Older
Controls resided in the same group of municipalities
corresponding to the catchment area of Copenhagen
University Hospital Hvidovre. Inclusion criteria were:
≥65 years of age, caucasian, no hospital admissions in
the 2 years preceding inclusion. Exclusion criteria were:
acute hospital admissions in the 2 years preceding inclu-
sion, current treatment with immunosuppressive or bio-
logical medication, and cancer or auto-immune illness
(see the full list of diagnoses and medication in Add-
itional File 1; Table S1 and S3). Potential participants
were identified by The Danish Health Data Authority via
the Danish Civil Registration System and the Danish Na-
tional Patient Registry and were invited to participate by
letter. Older Controls were asked to visit the Clinical Re-
search Centre at Copenhagen University Hospital Hvi-
dovre, for blood and data collection at inclusion and at a
follow-up visit after 1 year.
Young controls Inclusion criteria were: age between 20
and 35 years, caucasian, no hospital admission due to
chronic or severe illness in the 5 years preceding inclu-
sion (except childbirth, abortion, appendicitis, poisoning,
trauma, or concussion). Exclusion criteria were: auto-
immune or chronic illness (see the full list of diagnoses
and medication in Additional File 1; Table S2 and S3).
Young Controls were recruited by advertisement and
asked to visit the Clinical Research Centre for blood and
data collection at inclusion and at a follow-up visit after
30 days.
The present study includes data from the Patient
Group at hospital admission and at the follow-up visit
30 days after discharge, and from the Older and
Young Control groups at their respective inclusion
visits. One-year mortality status for participants from
the Patient Group and Older Control group is also
reported.
Whole blood stimulations and flow cytometry
Whole blood stimulations
Heparinized whole blood was rested for 15 min at 37 °C
prior to stimulation and subsequent freezing. Samples
were then incubated for 15 min at 37 °C with PBS (con-
trol), 1 μg/mL lipopolysaccharides (LPS) 055:B5 (Sigma-
Aldrich, St. Louis, MO, United States), or 100 ng/mL re-
combinant human TNF-α (BioLegend, San Diego, CA,
USA), or left unstimulated. Stimulated and unstimulated
samples were divided into 1 mL aliquots and incubated
with 1.4 mL Proteomic Stabilizer (Smart Tube Inc., Palo
Alto, CA, USA) at room temperature for fixation,
followed by storage at − 80 °C until thawing and anti-
body staining.
Antibody staining
Whole blood aliquots stored at − 80 °C were thawed in a
10 °C water bath, and red blood cells were lysed using
Thaw-Lyse Buffer (Smart Tube). Peripheral blood leuko-
cytes were then washed twice in cell staining media (2
mM EDTA (Life Technologies, Carlsbad, CA, United
States) and 0.5% bovine serum albumin (Miltenyi Biotec,
Bergisch Gladbach, Germany) in PBS). Cells were
permeabilized in 2 mL cold 100% methanol for 10 min at
4 °C and stored at − 80 °C overnight. Cells were then
washed twice in cell staining media and resuspended in
10% heat-inactivated human serum in PBS for 15min at
room temperature to block non-specific Fc receptor bind-
ing. Cells were stained for 45min at room temperature
with the following titrated antibody cocktail: anti-CD66b
(G10F5) AlexaFluor700 (BioLegend), anti-HLA-DR (L243)
Brilliant Violet 711 (BioLegend), anti-CD14 (61D3)
eFluor450 (eBioscience, San Diego, CA, USA), anti-CD16
(CB16) FITC (eBioscience), anti-NF-κB p65 (pSer529)
(K10–895.12.50) PE-CF594 (BD Biosciences), anti-NLRP3
(REA668) APC (Miltenyi Biotec). Cells were then washed
twice with cell staining media and analyzed on an LSRFor-
tessa (BD Biosciences) flow cytometer. Matching isotype
(AlexaFluor700 IgM (RnD Systems, Minneapolis, MN,
USA), Brilliant Violet 711 IgG2a κ (BioLegend), eFluor450
IgG1 κ (eBioscience), FITC IgG1 κ (eBioscience), PE-
CF594 IgG2b κ (BD Biosciences), and APC IgG2a κ (Mil-
tenyi Biotec)) and unstained controls were included for
each sample.
Flow cytometry
For each sample, 50,000 CD14 CD16 monocyte events
were recorded on an LSRFortessa flow cytometer (BD
Biosciences). Samples from matched Patient-Older Con-
trol pairs were assessed in the same batch. Compensa-
tions were generated for each fluorochrome using
CompBeads (Anti-Mouse Ig,κ; BD Biosciences) and anti-
mouse conjugated antibodies. Data were analyzed using
FlowJo v10 (BD Biosciences).
In addition, total monocyte numbers from fresh whole
blood samples were routinely measured by the Depart-
ment of Clinical Biochemistry, Copenhagen University
Hospital Hvidovre on a Sysmex XN-9000 analyzer (Sys-
mex Europe GmbH, Norderstedt, Germany).
Flow cytometry data analysis
The gating strategy for monocytes and monocyte subsets
was as follows: monocytes from whole blood were iden-
tified using their high forward/side scatter properties.
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Single cells were selected using a side scatter height ver-
sus area plot. Next, granulocytes were excluded based
on positive CD66b staining, and HLA-DR positive
monocytes were selected. Monocytes were then sub-
typed into three subsets based on CD14 and CD16 ex-
pression: classical (CD14++CD16−), intermediate
(CD14++CD16+), and non-classical (CD14+CD16+)
monocytes [28]. NF-κB signaling was assessed as (i)
basal NF-κB p65 phosphorylation (pNF-κB, p65/RelA
S529), reported as the median fluorescence intensity
(MFI); and (ii) the induction of NF-κB phosphorylation
in response to stimulation with LPS or TNF-α, reported
as fold change calculated as the transformed ratio of
pNF-κB MFI from the stimulated samples and control
sample on the log10 scale: log10(MFI of LPS or TNF-α)
– log10(MFI of PBS control). We also report expression
of HLA-DR and NLRP3 inflammasome.
Although 52 Patients were included, heparinized
whole blood samples were only available for 48 Patients
at admission. Due to logistical and technical reasons, we
were only able to analyze unstimulated (basal) samples
for subset distribution for: 42/48 Patients at admission,
and 50/52 at follow-up, 52/52 Older adults, and 60/60
Young Controls. LPS stimulation experiments were per-
formed for: 36/48 Patients at admission, 50/52 at Pa-
tients at follow-up, 52/52 Older Controls, and 20/60
Young Controls. TNF-α stimulation experiments were
performed for: 16/48 Patients at admission, 31/52 at Pa-
tients at follow-up, 52/52 Older Controls, and 20/60
Young Controls.
Plasma biomarker measurements
Blood samples were collected by venipuncture in anti-
coagulant EDTA containing tubes for plasma preparation.
Plasma levels of the chronic inflammation marker sol-
uble urokinase plasminogen activator receptor (suPAR)
for the Patient Group and Older Controls were mea-
sured by the Department of Clinical Biochemistry at
Copenhagen University Hospital Hvidovre using the
suPARnostic (ViroGates A/S, Birkerød, Denmark)
enzyme-linked immunosorbent assay (ELISA). Plasma
suPAR levels for Young Controls were measured by the
Clinical Research Centre at Copenhagen University Hos-
pital Hvidovre using the suPARnostic ELISA.
Levels of IL-1β, IL-6, IL-10, and TNF-α were mea-
sured using High Sensitivity Magnetic Luminex assays
(RnD Systems, Minneapolis, MN, USA). IL-18 levels
were measured using Magnetic Luminex assays (RnD
Systems) on the Luminex 200 System (Luminex Corpor-
ation, Austin, TX, USA). Growth differentiation factor
15 (GDF15), macrophage inflammatory protein-1α
(MIP-1α) and IL-8 levels were measured using Human
Quantikine ELISA assays (RnD Systems). All assays were
performed by the Clinical Research Centre, Copenhagen
University Hospital Hvidovre according to the manufac-
turer’s instructions. Samples were analyzed in duplicates
and if the intra-assay coefficient of variation was greater
than 20% for Luminex and 10% for ELISA, the samples
were re-analyzed. Samples from the Patient Group,
Older and Young Controls were distributed between as-
says, but admission and follow-up samples from the
same Patient and the sample for their matched Older
Control were analyzed in the same assay. Values below
the detectable range of the assays were assigned values
corresponding to the lowest detectable level, this was the
case for 92.7, 32.5, 88.2, 0.9, 0, and 0% of samples for IL-
1β, IL-6, IL-10, TNF-α, IL-18, and GDF15 respectively.
The average intra-assay coefficients of variation were
16.4, 8.1, 10.2, 4.4, 2.8, and 3.0% for IL-1β, IL-6, IL-10,
TNF-α, IL-18, and GDF15 respectively.
Background data and aging measures
Current smoking status was obtained via interview. An-
thropometric data included height (meters), weight (kg),
and body mass index (BMI; kg/m2).
Data on the reason for hospitalization reported by the
patients (categorized as cardiovascular symptoms, infec-
tions, respiratory symptoms, fall, or other reason), length
of hospital stay, and cause of death for the Patient
Group were collected from the patients’ electronic
health records.
We collected data on aging measures, including frailty,
physical and cognitive function. Frailty was assessed
using the frailty index (FI)-OutRef. FI-OutRef was devel-
oped in an acute care setting [29] and is calculated as
the number of biomarkers outside of reference range for
17 blood biochemistry biomarkers (alanine aminotrans-
ferase, albumin, alkaline phosphatase, bilirubin, blood
urea nitrogen, coagulation factors II, VII and X, C-
reactive protein (CRP), creatinine, hemoglobin, lactate
dehydrogenase, mean corpuscular hemoglobin concen-
tration, mean corpuscular volume, neutrophils, potas-
sium, sodium, thrombocytes, white blood cell count).
The biomarkers were routinely measured by the Depart-
ment of Clinical Biochemistry, Copenhagen University
Hospital Hvidovre.
Physical function was assessed using hand grip
strength, leg strength, and gait speed. Hand grip strength
(kg) was measured in the dominant hand (or strongest
hand for participants reporting loss of strength in the
dominant hand due to surgery or arthritis) using a hand-
held dynamometer (model Digi-II, Saehan Corp., Masan,
South Korea). The highest grip strength measurement
out of a minimum of three and maximum of five at-
tempts was used. Leg strength was assessed using the 30
s chair stand test and reported as the number of repeti-
tions. Gait speed (m/s: usual gait speed) was assessed
using the 4-m gait speed test. Participants were directed
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to walk at their normal pace, and the fastest of two at-
tempts was used.
Cognitive function was assessed using the Mini Mental
State Examination (MMSE) [30] and Trail Making Test
A and B [31]. For the Patient Group, these tests were
not administered at hospital admission.
Cytomegalovirus status
Cytomegalovirus (CMV) IgG levels were measured by
electrochemiluminescence on a COBAS platform at the
Department of Microbiology, Copenhagen University
Hospital Hvidovre. Samples with measurements below
the detectable range of the assay (0.150 U/mL) were
assigned values of 0.150 U/mL. Samples with values
below 0.5 U/mL were considered negative for CMV in-
fection (seronegative).
Statistical analyses
For descriptive statistics, continuous data are presented
as median and interquartile range (IQR) or mean and
standard deviation (SD) when normally distributed. Cat-
egorical data are presented as number of participants
and percentage. To assess differences between the Older
and Young Controls, we used Student’s t-test, Wilcoxon
rank-sum test, Chi-square or Fisher’s exact test where
appropriate. To assess differences between Patients at
admission and follow-up, and between Patients at
follow-up and Older Controls, we used paired t-test,
Wilcoxon signed-rank test, Chi-square or Fisher’s exact
test where appropriate.
We assessed differences in monocyte phenotypes and
NF-κB signaling between the Older and Young Controls
using Student’s t-test or Wilcoxon rank-sum test where
appropriate. We assessed differences in monocyte phe-
notypes and NF-κB signaling between Patients at admis-
sion and follow-up, and between Patients at follow-up
and Older Controls, using paired t-test or Wilcoxon
signed-rank test where appropriate. Mean and 95% con-
fidence intervals (95% CI) are reported for t-tests, and
median and IQR are reported for Wilcoxon tests.
We analyzed the associations of NF-κB signaling with
age, plasma biomarkers, frailty, and physical and cogni-
tive function in the Patient Group at follow-up and in
the Older Controls using simple linear regressions.
Plasma biomarker variables were log-transformed, and
estimates and 95% CI were back-transformed. Estimates
(β) and 95% CI indicate the change in the dependent
variable—expressed in the original unit, or in percent
change for plasma biomarkers—per 10% increase in
pNF-κB MFI. Furthermore, we assessed the association
of CMV infection with pNF-κB MFI in the Patient
Group and Older Controls using simple linear regres-
sions. pNF-κB MFI was log-transformed, and beta esti-
mates (β) and 95% CI were back-transformed and are
shown as percent difference in pNF-κB MFI for CMV
IgG seropositive individuals compared to seronegative
individuals.
We assessed the influence of monocyte NF-κB phos-
phorylation on the probability of belonging to the Pa-
tient Group (i.e. having a recent unplanned ED visit)
using conditional logistic regressions. We computed the
odds ratio (OR) estimates and 95% CI for belonging to
the Patient Group per 10% increase of basal pNF-κB
MFI in an unadjusted logistic regression model. Then,
we adjusted the model individually for each of the
plasma biomarkers, frailty, physical and cognitive func-
tion, and CMV-infection – all markers that we hypothe-
sized were mediators or confounders for the observed
effect.
Analyses were performed using Statistical Analysis
Systems (SAS) Enterprise Guide version 7.1 (SAS Insti-
tute, Cary, NC, USA). Graphs were made using Graph-
Pad Prism version 8 (GraphPad Software, San Diego,
CA, USA). A p-value < 0.05 was considered to indicate a
statistically significant difference.
Results
Baseline characteristics of the study participants
In total, 128 Patients, 52 Older Controls, and 60 Young
Controls were included in FAM-CPH. Out of the 128 in-
cluded Patients, one withdrew consent, 8 had died and
23 had dropped-out at the 30-day follow-up. Out of the
96 Patients remaining at follow-up, 42 were further ex-
cluded from this substudy due to autoimmune disease,
cancer, prescriptions for systemic immunosuppressive or
anti-inflammatory medication, or no blood samples
available for flow cytometry analysis. Thus, 54 Patients
could be age- and gender-matched with Older Controls.
We invited Older adults matched on age, sex, and muni-
cipality to the 54 Patients to participate in the study.
Due to a lower response rate than anticipated, we were
not able to fulfill the criteria for matching on municipal-
ity, but we included 52 Older Controls matched 1:1 on
age and sex to 52 of the Patients. One Young Control
was excluded from analyses due to reporting current ill-
ness and had elevated CRP levels, leaving 59 Young
Controls available for analyses. Thus, in total, data from
52 Patients, 52 age- and sex-matched Older Controls,
and 59 Young Controls were analyzed. The median age
for Patients and Older Controls was 75 years, and 48% of
participants were women. Young Controls had a median
age of 26 years and 49% were women (Table 1).
First, we assessed whether Patients had recovered from
acute illness at the 30-day follow-up. Patients were only
admitted for a median duration of 1 day (Table 1). At 30
days after discharge, levels of the acute inflammation
markers IL-6 (p < 0.0001) and CRP (p = 0.0006) were sig-
nificantly lower than at admission (Table 1). GDF15 levels
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Table 1 Characteristics of the study participants
Patient Group Older Controls Young Controls
Admission to the ED 30-day follow-up Inclusion Inclusion
n median (IQR) or n (%) n median (IQR) or n (%) n median (IQR) or n (%) n median (IQR) or n (%)
Demographics and lifestyle
Age (years)1 52 74.8 (70.6–81.8) 52 74.9 (70.7–82.0) 52 74.8 (70.7–81.9) 59 26.4 b (24.0–29.0)
Sex (women)2 52 25 (48.1) – 52 25 (48.1) 59 29 (49.2)
Smoking3–Daily smoker 52 6 (11.5) – 52 4 (7.7) 59 0 b (0)
Occasional smoker 0 (0) – 0 (0) 4 (6.8)
Former smoker 34 (65.4) – 29 (55.8) 13 (22.0)
Never smoked 12 (23.1) – 19 (36.5) 42 (71.2)
BMI (kg/m2)1 52 26.8 (23.0–31.5) 52 26.4 (22.2–31.7) 51 25.9 (22.7–27.9) 59 22.8 b (21.7–24.2)
Hospitalization
Length of stay (days) 52 1 (1–4) – – –
Reason for hospitalization 52
Cardiovascular symptoms 16 (30.1) – – –
Infection 11 (21.2) – – –
Respiratory symptoms 10 (19.2) – – –
Fall 5 (9.6) – – –
Other symptoms 10 (19.2) – – –
Plasma biomarkers
CRP (mg/L)4 52 6.2 (2.5–48.0) 52 3.2 ab (1.3–8.7) 51 1.2 (0.5–2.4) 59 0.4 b (0.3–0.9)
suPAR (ng/mL)4 50 3.2 (2.9–4.8) 52 3.3 b (2.6–4.7) 52 2.6 (2.2–3.1) 59 2.0 b (1.8–2.5)
IL-6 (pg/mL)4 49 2.4 (0.8–6.3) 52 0.8 ab (0.6–1.6) 52 0.6 (0.3–0.9) 59 0.3 b (0.3–0.3)
IL-18 (pg/mL)4 49 336.1 (213.0–434.2) 52 304.0 b (197.7–404.1) 52 216.9 (167.0–344.4) 59 183.8 b (144.4–239.0)
TNF-α (pg/mL)4 49 9.0 (7.0–13.3) 52 9.4 b (7.3–14.0) 52 8.2 (6.4–9.8) 59 5.3 b (4.4–6.1)
GDF15 (pg/mL)4 49 1873.5 (1177.1–2729.9) 52 1562.5 ab (1043.8–2186.2) 52 1003.9 (829.4–1297.0) 20 288.1 b (232.7–311.2)
Frailty
FI-OutRef1 50 4.3 (1.3–6.4) 52 3.2 b (1.1–5.3) 50 1.0 (0.0–2.0) 59 0.0 (0.0–1.0)
Physical function
4-m gait speed (m/s)1 37 0.75 (0.62–0.93) 50 0.79 ab (0.61–1.00) 52 1.25 (1.11–1.33) 59 1.43 b (1.33–1.54)
Hand grip strength (kg)1 51 22.5 (17.6–37.2) 51 25.4 ab (18.9–37.2) 52 30.8 (22.3–39.7) 59 39.8 b (33.8–50.4)
Chair stand test (repetitions)1 27 11 (9–14) 41 12 ab (9–14) 52 13 (11–16) 59 24 b (20–28)
Cognitive function
MMSE (points)1 – 47 29 (26–30) 52 29 (27–30) –
Trail making test A (seconds)4 – 47 50.0 b (37.0–69.0) 51 37.8 (29.0–54.6) 59 17.4 b (15.0–21.5)
Trail making test B (seconds)4 – 46 149.9 b (100.0–246.0) 49 86.9 (67.0–113.4) 59 44.5 b (38.7–53.5)
Mortality
1-year mortality3 52 4 (7.7) 52 0 (0) –
Cytomegalovirus status
Seropositive3 – 51 31 (60.8) 52 37 (71.2) 59 40 (67.8)
Anti-CVM IgG titer4 (U/mL) – 51 127.2 (0.2–461.5) 52 251.4 (0.2–424.2) 59 162.2 (0.2–410.1)
1 Paired t-test or Student’s unpaired t-test
2 Chi-square test
3 Fisher’s exact test or McNemar’s test
4 Wilcoxon signed-rank test or Wilcoxon rank-sum test
a p < 0.05 for comparison with admission values
b p < 0.05 for comparison with Older Controls
Abbreviations: BMI body mass index; CRP C-reactive protein; ED emergency department, FI-OutRef frailty index OutRef; GDF15 growth differentiation
factor 15; IL interleukin; MMSE mini mental state examination; suPAR soluble urokinase plasminogen activator receptor; TNF-α tumor
necrosis factor-alpha
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had also decreased at follow-up (p = 0.0005). Furthermore,
physical function also improved at follow-up (gait speed:
p = 0.005, hand grip strength: p = 0.003, and leg strength:
p = 0.0009; Table 1). FI-OutRef (p = 0.11) and levels of the
chronic inflammation marker suPAR (p = 0.16) as well as
levels of TNF-α (p = 0.76) and IL-18 (p = 0.48) were un-
changed between admission and follow-up (Table 1).
Next, we compared characteristics of Patients at
follow-up to Older Controls. Despite improvements
since hospitalization, Patients at the follow-up visit were
frailer (higher FI-OutRef, p < 0.0001), had higher CRP
(p = 0.0003), IL-6 (p = 0.005), and GDF15 (p < 0.0001)
levels and overall decreased physical function (gait
speed: p < 0.0001, hand grip strength: p = 0.009, leg
strength: p = 0.02) compared to the Older Controls
(Table 1). In addition, the inflammatory markers suPAR
(p < 0.0001), TNF-α (p = 0.005), and IL-18 (p = 0.02)
were elevated in the Patient Group compared to the
Older Controls (Table 1). Patients also had lower cogni-
tive function compared to the Older Controls (Trail
making test A p = 0.001, Trail making test B p < 0.0001),
although not when assessed using the MMSE (p = 0.31).
Four Patients had died within 1 year after the 30-day
follow-up visit (causes of death were: renal insufficiency
[n = 1], respiratory insufficiency [n = 1], cancer [n = 1],
unknown [n = 1]), while all Older Controls were alive 1
year after their inclusion (p = 0.12). At the 1-year follow-
up, Patients remained frailer than Older Controls (Add-
itional file 2. Table S4).
We then assessed differences in baseline characteristics
between Older and Young Controls. Young Controls had
lower BMI (p = 0.0008) and lower levels of the inflamma-
tory markers suPAR (p < 0.0001), CRP (p = 0.0002), IL-6
(p < 0.0001), IL-18 (p = 0.03) and TNF-α (p < 0.0001), as
well as GDF15 (p < 0.0001) compared to Older Controls
(Table 1). Young Controls also had better physical and
cognitive function (p < 0.0001 for all tests) compared to
the Older Controls (Table 1). FI-OutRef tended to be
lower in the Young Controls compared to Older Controls,
although this was not statistically significant (p = 0.07;
Table 1).
Plasma levels of IL-1β and IL-10, were only detected
in 7.3 and 11.8% of samples respectively and are there-
fore not included in the analyses. MIP-1α and IL-8 were
only measured in samples from 13 Patients at follow-up,
13 Older Controls, and 14 Young Controls but were un-
detectable in all samples.
Monocyte phenotypes
We first compared total monocyte numbers in each of
the groups. Total monocyte numbers in the Patient
Group were temporarily elevated at hospital admission
(mean: 0.74 × 109/L, 95% CI: 0.65 to 0.83) compared to
30-day follow-up (0.64 × 109/L, 95% CI: 0.58 to 0.70; p =
0.03). Monocyte numbers of Patients at follow-up were
not significantly different from that of Older Controls
(0.58 × 109/L, 95% CI: 0.53 to 0.63; p = 0.11). Young
Controls had fewer total monocytes (0.48 × 109/L, 95%
CI: 0.45 to 0.53, p = 0.002) than Older Controls.
We then assessed monocyte subset distribution and
HLA-DR expression in unstimulated whole blood sam-
ples using flow cytometry. An example of gating for
monocyte subsets is presented in Fig. 2a.
In the Patient Group, monocyte subset distribution
was unchanged between admission (mean percentage:
classical: 86.0, 95% CI: 83.8 to 88.1; intermediate: 4.1,
95% CI: 3.2 to 5.1; non-classical: 9.3, 95% CI: 7.8 to 10.8)
and 30-day follow-up (classical: 85.4, 95% CI: 83.7 to
87.2, p = 0.15; intermediate: 3.5, 95% CI: 2.6 to 4.1, p =
0.34; non-classical: 10.4, 95% CI: 9.0 to 11.8, p = 0.48;
Fig. 2b). In the total monocyte population, HLA-DR ex-
pression was lower at admission (median HLA-DR MFI:
1244, IQR: 959 to 1897) compared to follow-up (MFI:
1544, IQR: 1027 to 2176; p = 0.02; Fig. 2c), which could
be attributed to increased HLA-DR expression in the
classical (p = 0.004) and intermediate subsets (p = 0.03).
We then compared Older Controls to the Patient Group
at follow-up. There were no differences in subset distribu-
tion (classical: 85.5, 95% CI: 84.2 to 86.9, p = 0.63; inter-
mediate: 3.7, 95% CI: 3.3 to 4.2, p = 0.77; non-classical:
10.4, 95% CI: 9.3 to 11.6, p = 0.70; Fig. 2b) or HLA-DR ex-
pression (MFI: 1593, IQR: 1273 to 2179, p = 0.42; Fig. 2c)
of monocytes from Older Controls compared to the Pa-
tient Group.
Finally, we compared Older Controls to Young Controls.
Young controls had fewer non-classical CD14+CD16+
monocytes (8.4, 95% CI: 7.5 to 9.3, p = 0.007) than Older
Controls–and consequently a greater proportion of classical
CD14++CD16− monocytes (87.4, 95% CI: 86.2 to 88.6,
p = 0.04; Fig. 2b) compared to the Older Controls.
Monocytes from Young Controls also had higher
HLA-DR expression (MFI: 1968, IQR: 1451 to 2612,
p = 0.01; Fig. 2c) than monocytes from Older Con-
trols, which could be attributed to increased HLA-DR
expression in the classical subset (p = 0.01).
Monocyte NF-κB signaling
Next, we measured basal levels of NF-κB phosphoryl-
ation (pNF-κB; p65/RelA S529) and induction of NF-κB
phosphorylation upon stimulation with LPS or TNF-α in
total monocytes and their subsets (Fig. 3).
Within the Patient Group, basal pNF-κB levels at ad-
mission (pNF-κB MFI: 118, IQR: 102 to 135) were not
significantly different from follow-up levels (MFI: 125,
IQR: 105 to 153, p = 0.14; Fig. 3a). At admission, mono-
cytes from Patients were able to significantly induce NF-
κB phosphorylation in response to LPS (fold change:
0.10, 95% CI: 0.07 to 0.13, p < 0.0001, Fig. 3b) but not
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TNF-α (0.01, 95% CI: − 0.01 to 0.04, p = 0.20; Fig. 3c).
There were no associations of basal pNF-κB levels or re-
sponses to LPS or TNF-α stimulations at admission with
length of hospital stay or patient-reported reason for ad-
mission (data not shown). At follow-up, these responses
(LPS: 0.10, 95% CI: 0.08 to 0.12, p < 0.0001; and TNF- α:
0.02, 95% CI: − 0.00 to 0.05, p = 0.07) were not signifi-
cantly different compared to admission (p = 0.40; TNF-
α: p = 0.42).
Compared to the Patient Group at follow-up, Older
Controls had significantly lower basal pNF-κB levels
(MFI: 80, IQR: 71 to 90, p < 0.0001; Fig. 3a), and the
same trend was also observed within each of the
monocyte subsets. Monocytes from Older Controls were
able to significantly induce NF-κB phosphorylation in re-
sponse to LPS (0.13, 95% CI: 0.10 to 0.15, p < 0.0001;
Fig. 3b) and TNF-α stimulation (0.10, 95% CI: 0.08 to
0.12, p < 0.0001; Fig. 3c), and these responses were sig-
nificantly greater than those from the Patient Group at
follow-up (LPS: p = 0.05; TNF-α: p < 0.0001).
Compared to Older Controls, basal pNF-κB levels in
monocytes were not different in Young Controls (MFI:
81, IQR: 70 to 86; p = 0.72; Fig. 3a). Monocytes from
Young Controls were also able to significantly induce NF-
κB phosphorylation in response to stimulation by LPS
(0.40, 95% CI: 0.35 to 0.44, p < 0.0001; Fig. 3b) and TNF-α
Fig. 2 Monocyte subsets and HLA-DR expression. a Representative dot plot for the gating strategy for the CD14 CD16 monocyte subsets. b CD14
CD16 monocyte subset distribution in the Patient Group at admission (n = 42) and 30-day follow-up (n = 50), and Older (n = 52) and Young (n = 59)
Control groups. Paired t-test was used for comparison between Patient Group and Older Controls, unpaired t-test was used for comparison between
Older and Young Controls. c Total CD14 CD16 monocyte and subsets HLA-DR expression levels for the Patient Group at admission (n = 48 for total
monocyte and 42 for subsets) and at the 30-day follow-up (n = 52 for total monocyte and 50 for subsets), and Older (n = 52) and Young (n = 59)
Controls. Wilcoxon signed-rank test was used for comparisons between Patient Group at admission and 30-day follow-up, and between Patient Group
at 30-day follow-up and Older Controls, Wilcoxon rank-sum test was used for comparison between Older and Young Controls. Box plots depict
median and IQR, error bars indicate 95% CI. * indicates a p-value < 0.05
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(0.33, 95% CI: 0.27 to 0.40, p < 0.0001; Fig. 3c), and these
responses were significantly greater than those from Older
Controls (LPS: p < 0.0001; TNF-α: p < 0.0001).
We also measured NLRP3 inflammasome expression
in monocytes. NLRP3 expression followed the same pat-
tern as basal NF-κB phosphorylation. NLRP3 expression
was unchanged between admission (MFI: 57, IQR: 49 to
71) and follow-up in the Patient Group (MFI: 59, IQR:
47 to 71, p = 0.69, Additional File 3; Figure S1). Older
Controls had lower NLRP3 levels (MFI: 45, IQR: 35 to
54, p < 0.0001) than the Patient Group at follow-up.
Young Controls (MFI: 47, IQR: 38 to 55 p = 0.43; Add-
itional File 3; Figure S1) had similar levels than Older
Controls.
In all three groups, basal pNF-κB and NLRP3 levels
were highest in the CD14++CD16+HLA-DRhigh inter-
mediate monocyte subset (Fig. 3a and Additional File 3;
Figure S1). Induction of pNF-κB in response to LPS
Fig. 3 Basal and induced pNF-κB levels in monocytes. a Basal pNF-κB levels in monocytes from the Patient Group at admission (n = 46) and at
follow-up (n = 52), Older Controls (n = 52) and Young Controls (n = 59). b Fold change in pNF-κB levels in monocytes from the Patient Group at
admission (n = 36) and at follow-up (n = 50), Older Controls (n = 52) and Young Controls (n = 19) after stimulation with LPS for 15 min. c Fold
change in pNF-κB levels in monocytes from the Patient Group at admission (n = 16) and at follow-up (n = 31), Older Controls (n = 52) and Young
Controls (n = 19) after stimulation with TNF-α for 15min. Wilcoxon signed-rank test was used for comparison between Patient Group at admission and
30-day follow-up and between Patient Group at 30-day follow-up and Older Controls, Wilcoxon rank-sum test was used for comparison between
Older and Young Control groups. Box plots depict median and IQR, error bars indicate 95% CI. * indicates a p-value < 0.05
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stimulation was significantly different within each mono-
cyte subsets in all groups. The magnitude (high to low)
of pNF-κB induction in response to LPS in each subset
was as follows for the Patient Group at follow-up and
Older Controls: intermediate > non-classical > classical,
and for Young Controls: intermediate > classical > non-
classical (Fig. 3b). The induction of pNF-κB in response
to TNF-α stimulation was also significantly different
within each monocyte subsets in Older and Young Con-
trols. The magnitude of pNF-κB induction in response
to TNF-α in each subset was as follows for Older Con-
trols: intermediate > classical > non-classical, and for
Young Controls: classical > intermediate > non-classical.
No monocyte subset from the Patient Group could in-
duce pNF-κB signaling in response to TNF-α stimulation
(Fig. 3c).
Relationships between monocyte basal pNF-κB, chronic
inflammation, and aging measures
While Patients and Older Controls differed in the ability
of their monocytes to induce pNF-κB in response to
stimulation, they differed to a greater extend in their
monocytes’ basal pNF-κB levels. Thus, we investigated
associations of monocyte basal pNF-κB with chronic in-
flammation and aging measures in the Patient Group at
the 30-day follow-up and in Older Controls.
First, we assessed whether age and sex influenced
monocyte basal pNF-κB MFI in each group. In the Patient
Group, monocyte basal pNF-κB MFI was not dependent
on age (β: -0.41, 95% CI: − 1.5 to 0.7, p = 0.45) or sex (β:
1.76, 95% CI: − 12.5 to 18.4, p = 0.82). In Older Controls,
monocyte pNF-κB MFI increased by 1.22% per year (95%
CI: 0.5 to 2.0, p = 0.002) and was lower in men (β: -11.13,
95% CI: − 20.2 to − 1.0, p = 0.03). However, male partici-
pants were on average younger than female participants,
and the difference between male and female participants
became non-significant when adjusted for age (β: -8.48,
95% CI: − 17.5 to 1.5, p = 0.09).
In the Patient Group, there were no significant associ-
ations between monocyte pNF-κB MFI and any of the
inflammation or aging measures. In the Older Controls,
a 10% increase in monocyte basal pNF-κB MFI was sig-
nificantly associated with a higher FI-OutRef and higher
levels of the inflammatory markers IL-6 and TNF-α, and
tended to be associated with higher levels of suPAR and
decreased hand grip strength (Table 2). When adjusted
for age, the association of pNF-κB MFI with FI-OutRef
remained statistically significant (β: 0.23, 95% CI: 0.0 to
0.4, p = 0.02), while and the association of pNF-κB with
TNF-α (β: 3.22, 95% CI: − 0.4 to 7.0, p = 0.08) became
weaker and the association of pNF-κB with IL-6 was no
longer statistically significant (β: 7.39, 95% CI: − 3.3 to
19.3, p = 0.18).
Because CMV has been shown to activate NF-κB in
monocytes [32, 33], we also tested whether CMV IgG
seropositivity was associated with pNF-κB levels. CMV
IgG seropositivity was not associated with increased
pNF-κB MFI in the Patient Group (β: 8.02, 95% CI: − 7.0
to 25.4, p = 0.31) nor for Older Controls (β: -3.52, 95%
CI: − 14.8 to 9.3, p = 0.57).
Finally, we assessed the influence of monocyte NF-κB
phosphorylation on the probability of belonging to the
Patient Group (i.e. having a recent unplanned ED visit),
as well as possible mediating or confounding effects of
inflammation, frailty, physical and cognitive function,
and CMV infection on this relationship. The odds of be-
longing to the Patient Group increased by 80% for each
10% increase of pNF-κB MFI (Table 3). We then ad-
justed the logistic regression model for each marker of
inflammation, frailty, physical and cognitive function,
and CMV infection, individually. The OR estimate was
not affected by the adjustments, suggesting that none of
the markers were mediators or confounders for the rela-
tionship between monocyte basal pNF-κB and belonging
to the Patient Group. Of note, adjusting for GDF15
levels had the largest effect, by decreasing the odds of
belonging to the Patient Group from 80% to 69% per
10% increase in pNF-κB MFI.
Discussion
We assessed the effects of chronological age on mono-
cyte NF-κB signaling as well as differences between older
adults on different aging trajectories by comparing a
group of recently hospitalized older Patients to age-
matched Older Controls. Additionally, we assessed the
relationships between monocyte NF-κB signaling and in-
flammation, frailty, and physical and cognitive function
in older adults. Our results from comparisons between
Young and Older Controls showed that a higher chrono-
logical age is characterized by alterations in monocyte
phenotype and a decreased ability of monocytes to in-
duce NF-κB signaling in response to LPS and TNF
stimulation. The ability of monocytes to induce NF-κB
signaling in response to stimulation was further reduced
in the Patient Group compared to Older Controls, and
in particular, monocytes from the Patient Group showed
significant defects in their response to TNF-α induction
of pNF-κB signaling. The Patient Group also had signifi-
cantly elevated levels of inflammatory markers and ele-
vated basal NF-κB phosphorylation levels compared to
age-matched Older Controls (inflammaging). However,
associations of basal NF-κB phosphorylation with in-
flammatory markers and frailty were weak.
We designed this study with the aim of including two
groups of older individuals with different aging trajector-
ies. Frailty and comorbidity are important risk factors
for ED visits in older adults [34, 35]. Thus, we
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hypothesized that older adults requiring a visit to the ED
would be a heterogeneous, frail population with comor-
bidities, and thereby show signs of accelerated aging
compared to age-matched older adults without recent
hospital admissions. Although participants in the Patient
Group appeared to have recovered at the 30-day follow-
up visit, they still had lower physical function, were frai-
ler, and had elevated levels of inflammatory and senes-
cence markers (CRP, IL-6, IL18, TNF-α, suPAR, and
GDF15) [36] compared to age-matched Older Controls.
Additionally, at the one-year follow-up, the Patients
remained frailer than Older Controls and had elevated
levels of inflammatory biomarkers and reduced physical
and cognitive function. Furthermore, four Patients had
died after 1 year, while all Older Controls were still alive.
Therefore, we argue that the Patient Group exhibits ac-
celerated aging compared to the age-matched Older
Controls.
Several studies have shown that monocytes from older
adults have a higher basal production of cytokines, in-
cluding IL-1β, IL-6, IL-8, and TNF-α, compared to
monocytes from young adults [19, 22, 23, 37, 38]. These
cytokines are under transcriptional regulation of NF-κB,
therefore, we, and others, hypothesized that increased
NF-κB activity with age may be involved in the increased
production of cytokines (and thereby contribute to
inflammaging) [18]. We did not observe significant
differences in basal levels of NF-κB phosphorylation be-
tween Older and Young Controls despite the clear dif-
ferences in levels of inflammatory markers. Our results
are in contrast with a study by Qian et al. who found
higher levels of NF-κB in the nucleus of monocytes from
older compared to young individuals [20]. This discrep-
ancy could be due to differences in the method of quan-
tification of NF-κB (i.e. nuclear localization versus p65
S529 phosphorylation). Non-classical CD14+CD16+
monocytes have a pro-inflammatory profile and accumu-
late with age, and were therefore suggested to contribute
to chronic inflammation [19, 21, 23, 37, 39–41]. We ob-
served accumulation of non-classical CD14+CD16+
monocytes in older compared to young adults, but basal
pNF-κB levels did not differ in non-classical monocytes
from older and young adults. Moreover, we found that
intermediate monocytes had higher basal pNF-κB levels
than non-classical monocytes. While there is evidence
that unstimulated non-classical monocytes produce
higher levels of certain cytokines than intermediate and
classical monocytes, it is unclear whether it is a direct
result of increased basal pNF-κB activity, or whether it is
the result of increased activity of other pathways that are
specifically upregulated in non-classical monocytes such
as the MAPK/ERK pathway [39]. Furthermore, we only
found weak associations of basal pNF-κB levels with IL-
6 and TNF-α in older adults, challenging the role of
Table 2 Linear regressions for the associations of monocyte basal pNF-κB MFI with plasma biomarkers and aging measures in the
Patient Group at 30-day follow-up and Older Controls
Patient Group at 30-day follow-up Older Controls
Estimate (β) 95% CI P-value Estimate (β) 95% CI P-value
Plasma biomarkers
suPAR (ng/mL) a 1.48 (− 3.0–6.1) 0.51 3.16 (− 0.5–7.0) 0.09
CRP (mg/L) a 5.96 (−7.3–21.2) 0.39 7.62 (− 6.0–23.3) 0.28
IL-6 (pg/mL) a 3.92 (−4.4–13.0) 0.36 10.64 (0.4–21.9) 0.04
IL-18 (pg/mL) a 3.46 (−2.9–10.2) 0.29 3.08 (− 3.5–10.1) 0.36
TNF-α (pg/mL) a 2.72 (−3.3–9.1) 0.37 4.85 (1.4–8.5) 0.007
GDF15 (pg/mL) a 2.97 (−2.9–9.1) 0.32 1.67 (− 2.8–6.3) 0.46
Frailty
FI-OutRef −0.05 (− 0.3–0.2) 0.71 0.24 (0.1–0.4) 0.005
Physical function
4-m gait speed (m/s) 0.01 (−0.0–0.0) 0.35 0.00 (0.0–0.0) 0.80
Hand grip strength (kg) − 0.02 (− 1.3–1.3) 0.97 −1.17 (− 2.5–0.2) 0.08
Chair stand test (repetitions) 0.29 (−0.2–0.8) 0.23 −0.30 (− 0.8–0.2) 0.23
Cognitive function
MMSE (points) −0.03 (− 0.3–0.2) 0.82 −0.19 (− 0.4–0.1) 0.16
Trail making test A (seconds) −1.44 (− 6.2–3.5) 0.55 2.79 (−3.3–9.2) 0.37
Trail making test B (seconds) −1.24 (− 6.9–4.8) 0.67 3.82 (− 3.0–11.1) 0.27
a Variables were log-transformed, and estimates represent percent change in dependent variable per 10% increment in pNF-κB MFI
Abbreviations: CRP C-reactive protein, FI-OutRef Frailty index OutRef, GDF15 growth differentiation factor 15, IL interleukin, MMSE Mini Mental State Examination,
suPAR soluble urokinase plasminogen activator receptor, TNF-α tumor necrosis factor alpha
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S529 p65 NF-κB subunit phosphorylation in transactiva-
tion and upregulation of downstream inflammatory
genes in older individuals. Many other pathways such as
the JAK/STAT and MAPK/ERK play central roles in in-
flammatory signaling and may be involved in inflamma-
ging [39, 42, 43]. In particular, activation
(phosphorylation) of the JAK/STAT pathway in mono-
cytes was more strongly associated with age and circulat-
ing cytokine levels than the NF-κB pathway in a recent
study [42].
Monocytes from frail older adults have also been
shown to produce elevated levels of cytokines compared
to monocytes from non-frail older adults [44, 45]. In line
with these observations, we found elevated monocyte
basal pNF-κB and NLRP3 levels in older Patients with
signs of accelerated aging compared to age-matched
controls. It is unclear whether this is due to accumula-
tion of inflammatory non-classical monocytes in frail
older adults, we found both reports of unchanged and
increased proportions of CD14+CD16+ monocytes in
frail compared to non-frail older adults [46, 47]. Our re-
sults suggest that it is not the case, as we did not observe
differences in monocyte subset distribution between
Patients and age-matched Older Controls, furthermore,
NF-κB and NLRP3 levels were elevated in all monocyte
subsets. Inflammaging was recently proposed to result
from the accumulation of damage-associated molecular
patterns (DAMPs) [48, 49]. Patients had elevated FI-
OutRef compared to Older controls, reflecting accumu-
lation of organ damage which may cause elevated levels
of DAMPs and result in elevated monocyte basal pNF-
κB and NLRP3 levels. Furthermore, in the Older Con-
trols, basal pNF-κB was associated with FI-OutRef.
Immune function declines with age, however, it is un-
clear how monocyte function is affected. Reports are con-
flicting, but a majority of studies has shown that
monocytes of older adults produce reduced amounts of
cytokines than those of young adults upon Toll-like recep-
tor (TLR) stimulation [10, 19, 22, 23, 37, 38, 44, 50]. There
are also reports of reduced activation of the MAPK/ERK
and JAK/STAT pathways in response to TLR1/2 and cyto-
kine stimulation in older adults [37, 43]. Qian et al. ob-
served decreased total and phosphorylated p65 levels and
reduced NF-κB nuclear translocation in response to TLR5
stimulation in monocytes from older compared to young
individuals, despite a greater decrease in IκBα (inhibitor of
kappa B) levels in older individuals [20]. This is in line
with our results showing reduced pNF-κB induction in re-
sponse to TLR4 stimulation in monocytes from Older
compared to Young Controls. We also show a reduced in-
duction to tumor necrosis factor receptor (TNF-R) stimu-
lation, which has not been reported before. The only other
study–to our knowledge–to investigate differences in
monocyte NF-κB signaling in frail and non-frail older
adults reported no difference in NF-κB (S529), p38
MAPK, and ERK signaling in HLA-DR +CD11c + CD14+
monocytes stimulated with LPS or R848 [47]. However,
the authors did not report whether there were differences
in basal levels of NF-κB phosphorylation. We used a
higher concentration of LPS than the study by Compté
et al. [47] and we were able to show that pNF-κB induc-
tion in response to stimulation is slightly reduced in the
Patient Group compared to Older Controls. Furthermore,
pNF-κB induction in response to TNF-R stimulation in
monocytes from Patients was entirely blunted. Together,
our results demonstrate that monocyte responsiveness de-
creases with chronological age (immunosenescence) and
is further reduced in individuals with accelerated aging
compared to age-matched controls. Responses to both
LPS and TNF-α were affected. To the best of our know-
ledge, changes in TNF-R expression on monocytes with
age has not yet been studied, and reports of changes in
TLR4 expression are conflicting [20, 50, 51]. In addition
to the potential effect of age on TLR and TNF-R expres-
sion, impaired NF- κB activation could involve impaired
activity of molecules in the signaling pathways down-
stream of TLR4 and TNF-R. Thus, adding to the previous
Table 3 Logistic regression for the probability of belonging to
the Patient Group based on monocyte basal pNF-κB levels
OR Estimate 95% CI P-value
Unadjusted logistic regression 1.80 (1.3–2.4) < 0.0001
Adjusted for
Plasma biomarkers
suPAR (ng/mL) 1.78 (1.3–2.5) 0.0004
CRP (mg/L) 1.75 (1.3–2.4) 0.0003
IL-6 (pg/mL) 1.77 (1.3–2.4) 0.0001
IL-18 (pg/mL) 1.86 (1.4–2.5) 0.0001
TNF-α (pg/mL) 1.82 (1.3–2.5) 0.0002
GDF15 (pg/mL) 1.69 (1.2–2.3) 0.0009
Frailty
FI-OutRef 1.79 (1.2–2.6) 0.003
Physical function
4-m gait speed (m/s) 1.81 (1.3–2.5) 0.0001
Hand grip strength (kg) 1.77 (1.3–2.4) 0.0002
Chair stand test (repetitions) 1.74 (1.3–2.4) 0.0005
Cognitive function
MMSE (points) 1.76 (1.3–2.4) 0.0002
Trail making test A (seconds) 1.77 (1.3–2.4) 0.0004
Trail making test B (seconds) 1.99 (1.1–3.6) 0.02
CMV IgG seropositivity 1.82 (1.3–2.5) < 0.0001
Abbreviations: CMV cytomegalovirus, CRP C-reactive protein, FI-OutRef Frailty
index OutRef, GDF15 growth differentiation factor 15, IL interleukin, MMSE Mini
Mental State Examination, suPAR soluble urokinase plasminogen activator
receptor, TNF-α tumor necrosis factor alpha
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report of dysregulation of the NF-κB pathway with age
demonstrated by Qian et al. [20], we showed that one
mechanism for this dysregulation could involve defective
phosphorylation of the Ser529 residue of p65. The only
known kinase–to date–to phosphorylate the S529 residue
is Casein kinase II (CK2) [16, 52, 53]. CK2 activity down-
regulation is associated with cellular senescence [54], and
therefore further studies are needed to investigate if CK2
activity is affected by aging.
Expression of HLA-DR molecules on the surface of
monocytes is crucial for their function as antigen pre-
senting cells, linking innate and adaptive immune re-
sponses. Some studies have reported decreases in
monocyte HLA-DR expression with age [21, 55], while
others reported no change [56, 57]. Here, we show that
HLA-DR expression on monocytes decreased with
chronological age. This may have functional relevance,
and along with our observation of decreased NF-κB in-
duction upon stimulation in older adults, would provide
an additional mechanism for decreased immune respon-
siveness in older compared to young individuals. To the
best of our knowledge, HLA-DR expression has not yet
been investigated in relation to frailty or accelerated
aging. In our study, HLA-DR expression was not further
reduced in the Patient Group compared to Older Con-
trols, but was temporarily decreased during acute illness.
This is in line with reports of decreased HLA-DR ex-
pression on monocytes during systemic inflammatory re-
sponse syndrome (SIRS) and sepsis, reflecting a state of
immune suppression [58–60].
Our study has some limitations. First, we assessed NF-
κB signaling only by p65/RelA S529 phosphorylation.
While S529 phosphorylation is necessary for transactiva-
tion activity in a gene-specific manner, it is only one of
many phosphorylation sites distributed among many
protein subunits required for full transcriptional activity
of NF-κB [15, 16, 52, 61]. Furthermore, nuclear
localization, which was not assessed, is also necessary for
transcriptional activity. Because different phosphoryl-
ation sites, such as S536 or S276 are phosphorylated by
different kinases and have different impacts on the func-
tion of NF-κB, a more comprehensive evaluation of NF-
κB activity including nuclear localization and other
phosphorylation sites may better reveal different associa-
tions of NF-κB activity with chronic inflammation and
aging [15, 16, 52]. Second, although the Patient Group
appeared to have recovered from the acute
hospitalization with lower CRP and IL-6 levels and
regained physical strength at the 30-day follow-up visit.
It is possible that the recent hospitalization and acute ill-
ness had a confounding effect on the aging and immune
measures, and we observed sustained NF-κB signaling
between hospital admission and 30 days after discharge.
In older adults admitted for acute illness, although
recovery begins during hospitalization and mostly occurs
within the first month after discharge, many patients are
still recovering for several months [62–64]. Although Pa-
tients remained frailer than Older Controls after 1 year,
we did not assess monocyte function after the 30-day
follow-up and cannot exclude that NF-κB signaling in
Patients could be restored to levels similar to that of
Older Controls at a later time. Because patients were
acutely admitted, we could not collect data on aging and
immune measures prior to the onset of illness. This is a
challenge for the design of studies involving acutely hos-
pitalized older adults. Third, we did not collect informa-
tion on diagnoses and number of comorbidities in the
Patient Group and Older Controls and were therefore
unable to adjust for them in our analyses.
Conclusions
Our results did not provide clear evidence for the role of
monocyte NF-κB (p65/RelA pS529) signaling in age-
related chronic inflammation. However, altered mono-
cyte NF-κB signaling may play a role in accelerated aging
and frailty. Older chronological age was associated with
decreased monocyte NF-κB activation upon TLR4 and
TNF-R stimulation as well as a decreased expression of
HLA-DR molecules. Monocyte responses were further
reduced in individuals with signs of accelerated aging.
These alterations may contribute to impaired immunity
to infection and have implications for the success of
immunization in older adults and in populations with
accelerated aging. Further investigation of the pathways
involved in reduced monocyte function with age may
help finding strategies to restore function to innate im-
mune cells.
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